BCL2 and neoplasm: We may postulate that the translocations that lead to high BCL-2 and high MYC expression in DHL may arise at the GC B cell stage but that, as evidenced by the RNA-seq analysis, the high expression of MYC/BCL-2 is what drives the tumour signature.